NCT02639182View on ClinicalTrials.gov

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

October 2, 2020

Study Completion Date

October 2, 2020

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

AGS-16C3F

Intravenous (IV) infusion

DRUG

Axitinib

Oral

Trial Locations (26)

14263

Site US01006, Buffalo

15232

Site US01021, Pittsburgh

21201

Site US01023, Baltimore

27710

Site US01022, Durham

29425

Site US01011, Charleston

30322

Site US01010, Atlanta

48109

Site US01004, Ann Arbor

48202

Site US01013, Detroit

53226

Site US01009, Milwaukee

68130

Site US01012, Omaha

76508

Site US01014, Temple

77030

Site US01003, Houston

85719

Site US01026, Tucson

90033

Site US01007, Los Angeles

90095

Site US01020, Los Angeles

92093

Site US01008, La Jolla

94305

Site US01019, Palo Alto

97213

Site US01017, Portland

98109

Site US01001, Seattle

02215

Site US01002, Boston

T2N 4N2

Site CA02006, Calgary

T6G 1Z2

Site CA02004, Edmonton

V1Y 5L3

Site CA02005, Kelowna

V5Z 4E6

Site CA02001, Vancouver

L8V 5C2

Site CA02002, Hamilton

N6A 5W9

Site CA02008, London

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02639182 - A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter